$3.86
0.00% yesterday
Nasdaq, Sep 27, 10:05 pm CET
ISIN
US00437E1029
Symbol
ACCD
Sector
Industry

Accolade Stock News

Neutral
GlobeNewsWire
10 days ago
SEATTLE, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will release fiscal second quarter 2025 financial results on Tuesday, October 8, 2024 before market open. In conjunction, the company will host a conference call to review results at 8:00 a.m. E.T. on the same day.
Neutral
GlobeNewsWire
about one month ago
SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on Thursday, September 5 at 9:15 am ET.
Neutral
PRNewsWire
about one month ago
LITTLE ROCK, Ark. , Aug. 22, 2024 /PRNewswire/ -- Celeste Health Solutions (Celeste), a new company that will focus on merging the power of data insights, technology and personalized health management, is being introduced to the market to simplify healthcare access for employees while also easing the burden for employers.
Neutral
GlobeNewsWire
about 2 months ago
SEATTLE, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase in Boston on Wednesday, August 14 at 12:00 pm ET.
Neutral
Accesswire
2 months ago
NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ACCD.
Neutral
Accesswire
2 months ago
NEW YORK, NY / ACCESSWIRE / July 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ACCD.
Neutral
Accesswire
2 months ago
NEW YORK, NY / ACCESSWIRE / July 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ACCD.
Neutral
GlobeNewsWire
2 months ago
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. (“Accolade” or “the Company”) (NASDAQ: ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ACCD.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today